We thus performed a therapeutic experiment comparing romidepsin (approved use in relapsed/refractory PTCLs), rituximab, elotuzumab (anti‐SLAMF7 antibody approved for use in multiple myeloma), and combinations of these agents. The gene discussed is SLAMF7; the disease is plasma cell myeloma.